Aurinia Pharmaceuticals Inc.
NGM: AUPHLive Quote
About Aurinia Pharmaceuticals Inc.
Healthcare
Biotechnology
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
📊 Fundamental Analysis
Aurinia Pharmaceuticals Inc. demonstrates exceptional profitability, with a profit margin of 101.5%.
The company recently reported 28.8% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is 59.9%, which reflects exceptional capital efficiency.
At a current price of $15.76, AUPH currently trades near the top of its 52-week range (92%) (Range: $7.29 - $16.54).
💰 Valuation Insight
AUPH trades at a 69.5% discount (PE: 7.61), which may represent a value opportunity given the sector average of 25.00. Analysts anticipate some earnings pressure, with a higher forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
✅
Return on Equity
Excellent
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$2.03B
Trailing P/E
7.61
Forward P/E
19.22
Beta (5Y)
1.52
52W High
$16.54
52W Low
$7.29
Avg Volume
1.05M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App